Related Experiment Video
Updated: Nov 28, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Towards a better use of scientific advice for developers of advanced therapies
Anna Tavridou1, Dolca Rogers2, Milton Bonelli1
1Scientific Advice Office, Human Medicines Division, European Medicines Agency, Amsterdam, The Netherlands.
Abstract:
Scientific advice (SA) is an important tool offered by regulators to help developers generate robust evidence on a medicine's benefits and risks. Drawing on accumulated experience and looking at the SA provided by the European Medicines Agency in 2018 to advanced therapy medicinal products originally developed by public bodies, we discuss most commonly raised issues and the complexity and timings of the questions posed. Earlier and more frequent SA could help advanced therapy medicinal product developers to pre-empt delays at the marketing authorisation stage. Carefully addressing quality and nonclinical issues before entering the pivotal phase of development will clear the path for a smooth clinical development and successful marketing authorisation.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
06:18Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
Related Concept Videos
Preclinical Development: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Clinical Trials: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Microorganisms in Medicine and Therapeutics
iPS Cell Differentiation